香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月20日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江苏恒瑞医药股份有限公司 2025 年半年度报告 公司代码：600276 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [4]. Core Insights - The report highlights that Heng Rui Medicine has updated its innovative drug pipeline, entering a harvest period with 19 Class 1 innovative drugs approved for market, 11 in NDA stage, and 16 in Phase 3 clinical trials [2][18]. Summary by Sections Weekly New Drug Market Review - From March 31 to April 4, 2025, the top five companies in the new drug sector by stock price increase were: Hai Chuang Pharmaceutical (20.74%), Yi Ming An Ke (17.89%), Jia He Bio (15.20%), Kang Fang Bio (15.15%), and Mai Wei Bio (12.25%). The top five companies with the largest declines were: Chuang Sheng Group (-24.18%), Teng Sheng Bo Yao (-19.92%), He Bo Pharmaceutical (-17.76%), Mai Bo Pharmaceutical (-17.19%), and Ge Li Pharmaceutical (-12.75%) [1][14]. Key Analysis of the New Drug Industry - Heng Rui Medicine's 2024 annual report reveals its latest research pipeline as of March 2025, with 19 Class 1 innovative drugs approved, 11 in NDA stage, and 16 in Phase 3 clinical trials. The approved drugs include various treatments across oncology, metabolism, immunology, and cardiovascular fields [2][18][20]. New Drug Approvals and Acceptance - In the week, 10 new drugs or new indications were approved for market, 37 new drugs received IND approval, 19 new drugs had IND applications accepted, and 5 new drugs had NDA applications accepted [9][22]. Domestic New Drug Industry Focus - Key highlights include Heng Rui Medicine's JAK1 inhibitor, Aima Xitini (SHR0302), receiving approval for a new indication for adult patients with moderate to severe active rheumatoid arthritis. Additionally, the company has initiated Phase 3 clinical trials for its GLP-1 receptor agonist, HRS-7535, aimed at weight loss [10][30].